A peer-level look at how gastroenterology and hepatology clinicians identify MASLD fibrosis risk, where screening and referral pathways lose time, how FIB-4 and elastography are used, and what may help patients reach specialist care earlier.
Audience: Gastroenterologists & Hepatologists
Countries: 5
Completion Rate: 68.9%
SGID: 8935001
-Hero findings
– Quick Read — Key Findings
Current guidance increasingly focuses MASLD fibrosis assessment on high-risk metabolic groups and stepwise non-invasive testing, making primary-care recognition and referral thresholds central to earlier detection.
The 2026 American Gastroenterological Association clinical care pathway prioritizes three high-risk groups for fibrosis risk stratification, adults with type 2 diabetes, people with overweight or obesity plus another metabolic risk factor, and patients with incidental steatosis or elevated liver enzymes, using a two-tier approach that begins with a simple score such as FIB-4 and moves higher-risk patients to liver-stiffness measurement or another validated second-tier test.
The MDForLives survey sits directly inside that handoff, asking gastroenterology and hepatology clinicians who fills their screening workload, what prevents earlier identification, which NIT they use first, how much they trust current algorithms, where referrals originate, and at what fibrosis stage patients typically arrive. The pattern is less about whether tools exist than whether the pathway consistently brings the right patient to the right test at the right time.
68.8% say patients with obesity or metabolic syndrome make up the highest-volume cohort in their routine MASLD screening efforts.
Obesity and metabolic syndrome dominate the screening workload, accounting for 22 of 32 responses, with incidental liver-enzyme elevation a distant second at 18.8% and type 2 diabetes alone at 12.5%, consistent with the shift toward finding fibrosis inside metabolic care rather than waiting for liver-specific symptoms. Read against Finding 4, the same metabolic-risk patients who make up most of the volume are largely managed in primary care, which generates 80.6% of referrals, yet the modal patient still reaches specialist care at F2. A cohort being clinically obvious does not guarantee early staging: a patient can be recognizably high risk for years while fibrosis assessment is deferred or triggered only after another abnormality brings the liver into focus.
54.8% identify the asymptomatic nature of early-stage liver disease as the single greatest barrier to earlier MASLD detection.
Silent disease leads by a wide margin, with under-recognition and lack of routine primary-care screening at 16.1%, absent standardized pathways at 12.9%, the perception that fatty liver is benign at 9.7%, and limited NIT availability or cost last at 6.5%. That order is instructive: the tools largely exist and the process barriers are each individually small, which leaves silent disease as the obstacle awareness alone cannot solve. An asymptomatic disease cannot rely on symptoms to create urgency, so the pathway has to build the trigger itself, using risk factors, routine labs, or incidental findings to prompt fibrosis assessment before deterioration makes the problem obvious.
Transient elastography leads at 38.7%, only narrowly ahead of simple serum-based calculations such as FIB-4 at 35.5%.
First-line NIT choice is not dominated by one workflow: 12 of 31 respondents most often start with transient elastography (38.7%) and 11 with a simple serum score (35.5%), while blood biomarker panels and sequential FIB-4 then elastography are each 9.7% and MRE/MRI-PDFF is 6.5%. That near-tie matters because confidence is measured rather than absolute, 41.9% are moderately confident in current NIT algorithms, 35.5% very confident, 16.1% slightly, and only 6.5% extremely, so the absence of a shared first step likely feeds the uncertainty, and the gain lies in standardizing the sequence rather than adding another test.
80.6% say primary care or general practice generates most MASLD referrals, while 58.1% say patients most commonly present to their gastroenterology/hepatology practice with moderate/significant fibrosis (F2).
54.8% describe multidisciplinary collaboration as good but lacking formalized clinical protocols; another 32.3% say communication occurs while referral silos persist.
Only 3.2% describe collaboration as excellent and 9.7% call it poor and fragmented, leaving 87.1% in the informal or siloed middle, so the shortfall is structural rather than a lack of willingness. That is why the most-wanted fixes are operational: 35.5% choose wider availability and reimbursement for transient elastography, 25.8% standardized inter-specialty referral guidelines, and 19.4% automated FIB-4 inside primary-care EHRs, with education and awareness at 9.7% each. Looking further out, respondents expect both treatment and detection to advance, disease-modifying therapies lead at 38.7%, AI-driven prediction at 29.0%, and liquid biopsy or plasma biomarkers at 25.8%, but the near-term pathway still depends on access, staging, and referral rules.
The clinicians here are not describing a field without screening tools. Metabolic risk is obvious, non-invasive testing is already part of practice, and primary care generates most specialist referrals. The problem is that early disease can stay silent, first-line testing is not yet uniform, confidence in current algorithms is often moderate rather than absolute, and formal referral protocols lag day-to-day collaboration.
That makes the F2 finding important: for 58.1% of respondents, moderate or significant fibrosis is the most common stage at presentation. As fibrosis stage increasingly shapes management and therapeutic eligibility, the value of earlier detection becomes more concrete. The next improvement may depend less on another awareness message and more on making case-finding executable, identifying high-risk patients consistently, sequencing NITs clearly, expanding access to second-tier testing, and defining when a result should trigger specialist evaluation.
You have read the summary
Direct answers to common questions around this topic.
Direct answers to the questions healthcare professionals are most likely to ask about these findings.
